E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

GCTK announced a strategic business combination with Lōkahi Therapeutics, facilitated by E.F. Hutton as exclusive financial advisor. The transaction represents a typical M&A consolidation in the life sciences space, where smaller therapeutic players combine to achieve operational scale and shared R&D infrastructure. This type of deal is routine in biotech and rarely triggers broad market reactions.

Concurrent with the merger, the combined entity secured approximately $5.7 million in convertible note financing, arranged by E.F. Hutton as placement agent. This capital injection is modest relative to industry standards for post-combination growth, suggesting the combined company is pursuing near-term operational efficiency rather than aggressive expansion. Convertible structures indicate creditor willingness to assume equity upside if near-term cash generation remains uncertain.

The deal carries limited macro-market implications. E.F. Hutton's advisory role confirms institutional validation but does not signal sectoral momentum or broader investor appetite shifts. Health care consolidation activity remains fragmented and stock-specific rather than systematic.

Sector implication: Isolated biotech M&A activity with minimal systemic market correlation. No direct signals for Technology, Financial Services, or macro-sensitive sectors. Investor focus should remain on GCTK execution post-close and cash-burn trajectory rather than sector-wide therapeutics trends.